Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.
Treatment landscape of EGFR-mutant non–small cell lung cancer has evolved in the most recent years. In the metastatic setting, with combination approaches tested in first-line, whereas in the ...
Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...
The risk for acute kidney injury was not higher among patients with an eGFR dip at empagliflozin initiation. Previous studies have reported renal benefits with sodium glucose cotransporter 2 inhibitor ...
EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have oligometastatic ...
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study The Oncology Grand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results